



ASX ANNOUNCEMENT

10 December 2024

Opyl partners L39 Capital to Launch world first AI-Powered Biotech Investment Fund for active clinical trials using Trialkey across the USA and Australian equity markets.

Melbourne, Australia – Opyl Limited (ASX: OPL), a leader in clinical trial design and biostatistical validation, has partnered with L39 Capital Pty Ltd to launch the AI Biotech Fund a first-of-its-kind biotech investment fund. The fund capitalises on Opyl's TrialKey platform, which offers predictive analytics with 92% accuracy, providing a transformative edge for biotech investors.

By analysing over 468,429 clinical trials across 1,300+ variables, TrialKey delivers actionable insights into clinical trial success probabilities, enabling precision trading at high-impact inflection points during Phase 2 and Phase 3 trials.

L39 Capital Commentary:

"We are excited to partner with Opyl to launch this innovative AI-powered biotech fund. TrialKey's advanced analytics offer a significant advantage in identifying promising investment opportunities. Combined with our proprietary trading system we believe this fund will deliver strong returns for our investors while driving innovation in the biotech industry."

Key Highlights

- Establishment of AI-Powered Fund: The fund is targeting Funds Under Management (FUM) to AUD \$100 million over three years.
- Strategic Focus on Clinical Trial Inflection Points: Utilises predictive analytics to target investments at key milestones in Phase 2 and Phase 3 clinical trials, facilitating up to 200 trades annually.
- Initial Portfolio and Expansion Plan: Launching with 20 initial investments across the United States and Australia, with strategic expansion into the United Kingdom and other international markets.



- Revenue Model for Opyl: Includes an AUD \$25,000 software license fee and a 25% share of fund income, recognising Opyl's proprietary AI platform as central to the fund's operational success.
- Notable Backers and Advisors: Supported by industry leaders including Antanas Guoga, and Damon Rasheed and L39 Capital.
- Open to Wholesale Investors: Targets professional investors with a structured, technology-driven methodology to diversify exposure and optimise returns within the biotech sector.

Revenue Structure

Opyl will generate revenue through a dual fee model:

1. Software License Fee: AUD \$25,000 granting initial access to TrialKey's platform.
2. Share of Income: Opyl will receive 25% of the fund's income, reflecting its integral role in the fund's strategy and performance.

Data-Driven Trading Strategy

The fund's strategy is built around TrialKey's real-time predictive analytics, identifying moments of peak value creation during clinical trials. These insights support up to 200 precision trades annually, with an initial focus on 20 investments in the United States and Australia.

This data-backed methodology aims to reduce risk and improve returns, providing investors with unparalleled access to high-potential biotech and pharmaceutical companies.

An average clinical trial has a 28% chance of success yet TrialKey has uncovered trials with over 82% chance of success almost 3 times higher than the average.

Cutting-Edge TrialKey Technology

At the core of this initiative lies TrialKey, a proprietary AI platform designed to provide biotech investors with a competitive advantage. Key features include:

- 92% accuracy in predicting clinical trial completion, setting a new standard for investment decision-making.
- Analysis of over 468,429 clinical trials and 1,300+ variables, offering unparalleled depth of insight.



- 200+ market inflection points identified annually, enabling timely, high-impact investment decisions.
- Trial prediction often highlights more than 3 times the average chance of trial success before readout.

AI Biotech Fund Pty Ltd Investor Commentary

Antanas Guoga, a director of Opyl Limited and a backer of the fund, commented:

“TrialKey’s AI platform is a game-changer for biotech investors. Its unparalleled predictive accuracy and ability to identify key moments in clinical trials redefine how we approach investment strategies in the pharmaceutical industry. I’m proud to back a fund with this level of technological sophistication and market potential”.

Regulatory Compliance

The AI Biotech Fund Pty Ltd operates as a Corporate Authorised Representative of Non Correlated Advisors Pty Ltd.

- **CAR Number:** 001312461
- **AFSL Number:** 430 126
- **Authorised Activity:** AI Biotech Fund Pty Ltd is authorised to provide general advice to wholesale investors only.

Opyl Director Involvement

ITE Marketing and Investment Pty Ltd, acting as Trustee for the Rasheed Family Trust, will hold a 5% equity stake in AI Biotech Fund Pty Ltd, which was awarded for his seed investment into the fund, part of which was used to fund initial expenses. This trust, partially owned by Opyl’s Executive Director and Chief Technology Officer, Damon Rasheed, underscores his pivotal role in incorporating Opyl’s TrialKey technology into the fund’s operations. This equity position reflects a strong alignment between Opyl’s leadership and the fund’s strategic objectives, further reinforcing Damon Rasheed’s commitment to the fund’s success.

For personal use only



Antanas Guoga, a globally recognised investor with a proven track record of successful ventures, holds a 5% equity stake in AI Biotech Fund Pty Ltd through his private investment entity. This equity was awarded in recognition of his strategic advisory role and seed investment in the fund. As a director of Opyl Limited, Antanas Guoga's involvement brings significant expertise in technology-driven investments and global market expansion.

Global Expansion Plan

The fund will commence with 20 targeted investments in the United States and Australia, with plans to expand into the United Kingdom and other regions. Its structured methodology ensures diversified exposure to promising biotech companies and includes up to 200 trades per year based on critical clinical trial inflection points.

Unlocking Value for Biotech Investors

This fund represents a significant advancement in biotech investing, combining data-driven insights with AI-enabled trading strategies to deliver superior returns. Wholesale investors gain access to a structured, technology-forward methodology that reduces uncertainty while maximising opportunities in a dynamic and high-stakes sector.

How to Participate

The Fund is now open for applications to wholesale and sophisticated investors. If you wish to participate, please email info@aiotechfund.com or visit aiotechfund.com and fill in the Interest Form.

Minimum investment is \$50,000.

This announcement has been authorised for release by the board

-ENDS-



For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice.averion@opyl.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.

About AI Biotech Fund

The AI Biotech Fund is an innovative sophisticated and wholesale investment vehicle focused on generating significant capital appreciation by leveraging advanced AI-driven strategies in clinical trial assessment. The fund will invest in biotech and pharmaceutical stocks that are undergoing clinical trials with near-term readouts that are expected to lead to significant movements in share prices.